Rituximab immunotherapy combined with dexamethasone followed by 90Y-ibritumomab tiuxetan radioimmunotherapy in pretreated patients with relapsed follicular lymphoma

Česká verze

Authors: T. Papajík ¹; T. Szotkowski ¹; V. Procházka ¹ ; Z. Kubová ¹; V. Heinzová ²; M. Brejcha ³; J. Drymlová ⁴; E. Buriánková ⁴; P. Koranda ⁴; M. Mysliveček ⁴; L. Kučerová ⁵; K. Indrák ¹
Authors place of work: Hemato-onkologická klinika FNO a LF UP v Olomouci, 2Hematologické a transfúzní oddělení nemocnice Opava ¹; Onkologické centrum J. G. Mendela Nový Jičín, 4Klinika nukleární medicíny FNO a LF UP v Olomouci ³; Oddělení patologie FNO a LF UP v Olomouci ⁵
Published in the journal: Transfuze Hematol. dnes,13, 2007, No. 4, p. 209-215.
Category: Souhrnné práce, původní práce, kazuistiky

Summary

The introduction of monoclonal antibody therapy has provided hope for the patients with follicular lymphoma (FL) that their prognosis may be improved. Rituximab (anti-CD20 chimeric monoclonal antibody, MabThera^®) has proven to be highly effective and non-toxic targeted treatment of FL. The response rate and therapeutic benefit of monoclonal antibodies seems to be enhanced by the use of radioisotope-labelled antibody therapy. 90Y-ibritumomab tiuxetan (Zevalin^®) was the first radioimmunotherapy (RIT) approved for the treatment in relapsed or refractory FL and many clinical trials demonstrated its efficacy and safety even in patients with advanced stage disease. According to new studies, RIT should be preferably used as consolidation treatment after tumor debulking. We report 3 patients with relapsed FL treated with four weekly doses of rituximab (375 mg/m²) and dexamethasone (20 mg/m²) with respect to their age, previous therapy, concomitant diseases or some concerns about chemotherapy complications. All patients responded to rituximab, but residual disease was demonstrated in each of them. Therefore, it was decided to treat them with 90Y-ibritumomab tiuxetan RIT in a dose of 14,8 MBq/kg in two patients and 11,1 MBq/kg in one patient (with platelet counts 125x109/l). Hematological nadirs were reached 4–6 weeks later, with one grade 3 neutropenia, one grade 4 and one grade 3 thrombocytopenia, respectively. Two patients had minor infection complications (acute bronchitis and enteritis). From 2 to 3 months after radioimmunotherapy, the 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) analysis proved no accumulation of 18F-FDG in any lymph node (LN) and computed tomography (CT) scans documented LN with the maximum size of 2x1 cm in two patients (one CR, two CRu). Eleven, nine and seven months after RIT, the patients were subjectively well, clinically in durable disease remission without any late complications.

Key words:
folicullar lymphoma, 90Y-ibritumomab tiuxetan, rituximab, positron emission tomography, remission

Zdroje

1. Hiddeman W, Buske C, Dreyling M, et al. Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives. J Clin Oncol 2005; 23 : 6394-6399.

2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. J Clin Oncol 1998; 16 : 2825–2833.

3. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17 : 268–276.

4. Cheson BD. Radioimmunotherapy of non-Hodgkin’s lymphoma. Blood 2003; 101 : 391–398.

5. DeNardo GL, O’Donnell RT, Shen S, et al. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin’s lymphoma. J Nucl Med 2000; 41 : 952–958.

6. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin’s lymhoma. Sem Oncol 2002; 29 (Suppl 2): 87–92.

7. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17 : 3793–3803.

8. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lym-phoma. J Clin Oncol 2002; 20 : 2453–2463.

9. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103 : 4429–4431.

10. Ansell SM, Ristow KM, Hanermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibrituomomab tiuxetan fo non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20 : 3885–3890.

11. Emmanoulides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 2006; 47 : 629–636.

12. Jacobs SA , Vidnovic N, Joyce J, et al. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11 : 7146–7150.

13. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329 : 987–994.

14. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma prognostic index. Blood 2004; 104 : 1258–1265.

15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomnas. J Clin Oncol 1999; 17 : 1244–1253.

16. Shipley DL, Spigel DR, Carell DL, et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol ASCO Annual Meeting Proceedings 2004; 22 (Suppl 14): 6519.

17. Jurczak WJ, Szostek MS, Giza AG, et al. Consolidation of chemotherapy response in mantle cell lymphoma (MCL) patients with 90Y-ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT). Haematologica 2006 : 91 (Suppl. 1): 188.

18. Dreyling M, Trümper L, von Schilling C, et al. Results of national consensus workshop: therapeutic algorithm in patients with follicular lymphoma –⁠ role of radioimmunotherapy. Ann Hematol 2007; 86 : 81–87.

19. Rose AL, Smith B, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002; 100 : 1765 –⁠ 1773.